✓ No loaded language, vague sourcing, or framing detected.
The FDA advisory committee is considering Moderna's mRNA-based flu vaccine, mFlusiva, aimed at individuals aged 50 and older. This review is a step toward a final decision before the winter flu season.
Our neutral summary
The FDA advisory committee is considering Moderna's mRNA-based flu vaccine, mFlusiva, aimed at individuals aged 50 and older. This review is a step toward a final decision before the winter flu season.
The reporting belongs to Guardian — US; we don't reproduce it.
No note attached
on this article.
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
FDA Panel Reviews Moderna's mRNA Flu Vaccine for Older Adults